Compounded semaglutide and tirzepatide became widely available during 2023 and 2024 shortages, but as commercial supply returned, most compounding of these specific molecules is no longer permitted
16 17 18 Newly emerging indications for GLP-1 medicationsincluding heart disease, metabolic liver disease, peripheral artery disease, Alzheimers/dementia risk, and even alcohol and substance use disorders, as highlighted in a 2025 study in JAMA 19 suggest these drugs may soon play a much broader role in medicine than just treating diabetes or obesity
2024: Wiley Online Library
This gives you the needed information to discuss whether they should be added to your healthcare regimen when you speak to your healthcare provider
Journal of Cellular Physiology, 2012, 227(6):1814-1820 172
Check each providers policy, as this is where customer service quality becomes particularly important